Scotts Miracle-Gro Company Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $3.5B-1.9% YoYTTM through 27 Jun 2026
Net Income $73.9MTTM through 27 Jun 2026
Free Cash Flow $263.3MTTM through 27 Jun 2026
Margins
| Current | |
|---|---|
| Gross Margin | 30.6% |
| EBITDA Margin | 13.3% |
| Operating Margin | 10.5% |
| Net Margin | 2.1% |
Returns
-40.6%ROE
5.3%ROA
3.9%ROIC
Balance Sheet Health
Debt / Equity-5.95x
Current Ratio1.21x
Net Debt$2.1B
Cash & Equivalents$27.7M
Quality Metrics
Altman Z-Score2.31
Piotroski F-Score7 / 9
FCF Margin7.6%
Earnings-Beat Rate100.0%
Multi-Year Trend
RevenueFY2025: $3.4B
Diluted EPS$1.22TTMFY2025: $2.47
Dividend
$1.32Per share, FY20262.51%Yield-12.4%5-yr growth
Capital Allocation
R&D Spend$34.8M
Capex Intensity3.0%
Segment Performance
| Segment | Revenue | YoY | Outlook |
|---|---|---|---|
| U.S. Consumer | $3B | View detailsReaffirmed fiscal 2026 guidance of low single-digit net sales growth. | |
| Hawthorne | $130.2M | View detailsClassified as a discontinued operation in Q1 fiscal 2026 and sold to Vireo Growth Inc. on April 8, 2026. |
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.